Application of medication composition of containing ligusticum in preparing medicine for treating chronic cerebral circulation insufficin

Abstract

An application of the medicinal composition composed of 8 Chinese-medicinal materials including Chuan-xiong rhizome, red sage root, gastrodia tuber, pueraria root, etc in preparing the medicines for treating chronic cerebral ischemia is disclosed.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of a medicinal composition containing Ligusticum edulis in the preparation of medicine for treating chronic cerebral insufficiency. Background technique [0002] The origin of the concept [0003] Chronic Cerebral Circulation Inefficiency (CCCI) refers to the state of reduced blood supply to the brain at the overall level (less than 40-60ml / 100g brain tissue / minute), rather than focal cerebral ischemia. It is a relatively new disease name proposed by foreign countries in the first 10 years. Clinically, some elderly or pre-senile patients who repeatedly complain of subjective symptoms such as heavy head and dizziness have neither focal signs of nerve damage nor brain CT abnormalities except fundus arteriosclerosis. Arteriosclerosis". It is well known that the concept and clinical diagnostic criteria of cerebral arteriosclerosis have been divergent for a long...

AI Technical Summary

Problems solved by technology

[0035] 3. No focal neurological signs of the brain

[0046] 3. No focal neurological signs of the brain;

[0047] 4. CT\MRI without vascular organic brain changes;

[0061] At present, the drugs used clinically to treat CCCI include: THA: cholinesterase inhibitor, GST-21: central N-choline receptor inhibitor, FK506: immunosuppressant, Nimsuperzine: Cox-2 inhibitor, etc. Good short-term clinical curative effect has been achieved, but the long-term curative effect needs to be further studied

Images